Sugi Predict

Sugi Predict / Compounds / SCHEMBL15535667

SCHEMBL15535667

SCHEMBL15535667

OCc1ccc(CC(F)(F)F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.43
▸ KIF11 P52732 2/20 0.42
▸ PRSS1 P07477 1/20 0.39
▸ PRSS2 P07478 1/20 0.39
▸ PRSS3 P35030 1/20 0.39
▸ NR1I2 O75469 1/20 0.39
▸ VHL P40337 1/20 0.38
▸ ELOC Q15369 1/20 0.38
▸ ELOB Q15370 1/20 0.38
▸ LTA4H P09960 1/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA4 P22748 1/20 0.38
▸ CA6 P23280 1/20 0.38
▸ CA5A P35218 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ CA14 Q9ULX7 1/20 0.38
▸ CA5B Q9Y2D0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7670360 0.86 ESR1 (0.38) TSHRESR1
SCHEMBL2174894 0.79 ESR1 (0.58) CA12CA1CA2CA4CA5A
SCHEMBL41775 0.76 TSHR (0.67) TSHRKIF11PRSS1PRSS2PRSS3
SCHEMBL10570 0.76 ALDH1A1 (0.52) TSHRKIF11
SCHEMBL10248786 0.76 IDO1 (0.48) —
SCHEMBL25343430 0.75 ESR1 (0.43) ESR1
SCHEMBL28043083 0.75 NR1I2 (0.41) NR1I2ESR1
SCHEMBL14392748 0.74 CYP3A4 (0.41) —
SCHEMBL21875041 0.74 TRPV4 (0.34) ESR1
SCHEMBL21507936 0.74 ESR1 (0.31) ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011313-A1 CCR6 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2025-01-09 — — US disclosed
US-20240299559-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2024-09-12 — — US disclosed
US-11667606-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-06-06 — — US disclosed
US-11667606-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-06-06 — — US disclosed
WO-2023069700-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2023-04-27 — — WO disclosed
US-20220047540-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS ORION CORP (FI) 2022-02-17 — — US disclosed
CN-113784950-A Novel thyromimetic agents 速通医疗公司 2021-12-10 — — CN disclosed
US-20210053917-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2021-02-25 — — US disclosed
US-20210053917-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2021-02-25 — — US disclosed
US-20200352898-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS ORION CORP (FI) 2020-11-12 — — US disclosed
US-20190029990-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS ORION CORP (FI) 2019-01-31 — — US disclosed
US-20170165219-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS ORION CORP (FI) 2017-06-15 — — US disclosed
CN-104334525-B catechol O-methyltransferase activity inhibiting compounds 奥赖恩公司 2017-05-10 — — CN disclosed
EP-2855426-B1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS ORION CORP (FI) 2017-01-04 — — EP disclosed
US-9458128-B2 Catechol O-methyltransferase activity inhibiting compounds ORION CORPORATION (FI) 2016-10-04 — — US disclosed
US-20150218124-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS ORION CORPORATION (FI) 2015-08-06 — — US disclosed
EP-2855426-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS Orion Corporation (FI) 2015-04-08 — — EP disclosed
CN-104334525-A Catechol o-methyltransferase activity inhibiting compounds ORION CORP 2015-02-04 — — CN disclosed
WO-2013175053-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS ORION CORPORATION (FI) 2013-11-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11667606-B2 Thyromimetics TPO, TSHR, TTR TSHR 2/4885KIF11 2389/4885PRSS1 719/4885
US-20170165219-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS COMT, PNMT, HNMT TSHR 2534/4885KIF11 4172/4885PRSS1 712/4885
US-20200352898-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS COMT, PNMT, HNMT TSHR 2534/4885KIF11 4172/4885PRSS1 712/4885
US-20250011313-A1 CCR6 RECEPTOR MODULATORS CCR6, CCR1, CCR4 TSHR 543/4885KIF11 3314/4885PRSS1 2493/4885
US-20190029990-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS COMT, PNMT, HNMT TSHR 2534/4885KIF11 4172/4885PRSS1 712/4885
US-20240299559-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF CDK2, SKP2, CDK1 TSHR 3902/4885KIF11 2701/4885PRSS1 2002/4885
US-20210053917-A1 NOVEL THYROMIMETICS TPO, TSHR, CHRM1 TSHR 2/4885KIF11 1707/4885PRSS1 582/4885
US-20150218124-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS COMT, PNMT, HNMT TSHR 2534/4885KIF11 4172/4885PRSS1 712/4885
US-20220047540-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS COMT, PNMT, HNMT TSHR 2534/4885KIF11 4172/4885PRSS1 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.